Antituberculous vaccine development: a perspective for the endemic world.

Area of Science:

• Immunology
• Vaccinology
• Infectious Diseases

Background:

• Bacillus Calmette-Guérin (BCG) is the only licensed tuberculosis vaccine.
• Several new antituberculous vaccine candidates are in early clinical trials.
• Existing vaccines face challenges in diverse endemic settings.

Purpose of the Study:

• To review current BCG vaccine and new TB vaccine candidates.
• To assess the potential efficacy of new vaccines in high-burden countries.
• To identify the specific needs for effective TB vaccines in endemic regions.

Main Methods:

• Review of preclinical and early-phase clinical trial data.
• Analysis of vaccine strategies including subunit, recombinant BCG, and vector-based approaches.
• Consideration of challenges in endemic settings: prior BCG vaccination, environmental mycobacteria exposure, latent TB, and HIV co-infection.

Main Results:

• New vaccine candidates demonstrate efficacy in preclinical models.
• Clinical trials are evaluating subunit vaccines, recombinant BCG, and boosted BCG immunity.
• Uncertainty exists regarding the effectiveness of current candidates in diverse, endemic populations.

Conclusions:

• The efficacy of new TB vaccines in endemic regions with complex challenges is a critical question.
• Vaccine strategies must address BCG-vaccinated individuals, environmental mycobacteria exposure, and co-infections (latent TB, HIV).
• Further research is essential to develop TB vaccines tailored for high-burden endemic countries.